Details for Patent: 10,653,710
✉ Email this page to a colleague
Which drugs does patent 10,653,710 protect, and when does it expire?
Patent 10,653,710 protects TIBSOVO and is included in one NDA.
This patent has thirty patent family members in twenty-seven countries.
Summary for Patent: 10,653,710
| Title: | Combination therapy for treating malignancies |
| Abstract: | Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethy- l)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-car- boxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent. |
| Inventor(s): | Agresta; Samuel V. (Lexington, MA), Viswanadhan; Krishnan (East Hanover, NJ), DiMartino; Jorge (Belmont, CA), Chopra; Vivek Saroj Kumar (South San Francisco, CA), MacBeth; Kyle J. (San Francisco, CA), Knight; Robert Douglas (Berkeley Heights, NJ), Kenvin; Laurie (New Hope, PA), Xu; Qiang (Bernards, NJ) |
| Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) Celgene Corporation (Summit, NJ) |
| Application Number: | 15/767,822 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,653,710
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,653,710
| PCT Information | |||
| PCT Filed | October 14, 2016 | PCT Application Number: | PCT/US2016/057042 |
| PCT Publication Date: | April 20, 2017 | PCT Publication Number: | WO2017/066571 |
International Family Members for US Patent 10,653,710
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016338557 | ⤷ Try a Trial | |||
| Brazil | 112018007656 | ⤷ Try a Trial | |||
| Canada | 3002068 | ⤷ Try a Trial | |||
| Chile | 2018000943 | ⤷ Try a Trial | |||
| China | 108697698 | ⤷ Try a Trial | |||
| Cyprus | 1124951 | ⤷ Try a Trial | |||
| Denmark | 3362066 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
